Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM (Q84592604)
Jump to navigation
Jump to search
scientific article published on 28 September 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM |
scientific article published on 28 September 2009 |
Statements
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study (English)
Bella Kaufman
Michael R Clemens
Poonamalle P Bapsy
Ashok Vaid
Sergei Tjulandin
Michaela Jahn
Michaela Lehle
Andrea Feyereislova
Cédric Révil
28 September 2009